Introduction
Von Willebrand factor (VWF), a multimeric glycoprotein, is required for normal hemostasis. VWF forms adhesive strings that mediate platelet adhesion and aggregation to sites of vascular damage [1] . VWF is primarily produced by endothelial cells (ECs) and is either constitutively secreted or stored in rod-shaped Weibel-Palade bodies (WPBs) [2] . Deficiency or dysfunction of VWF can cause von Willebrand disease (VWD) -the most commonly inherited bleeding disorder in humans affecting 0.1-1% of the population [3, 4] . The International Society on Thrombosis and Haemostasis currently recognizes three types of VWD: type 1 -the least severe form of the disease resulting from a partial quantitative VWF deficiency; type 2 -qualitative VWF abnormalities; and type 3 -the most severe form of the disease resulting from negligible VWF levels [5] . Type 2 VWD has four subtypes: type 2A results from absence of the most haemostatically active high molecular weight multimers; type 2B occurs through increased VWF-platelet interactions causing accelerated clearance of haemostatically active high molecular weight multimer and thrombocytopenia; type 2M results from a loss of platelet-binding function; and type 2N is characterized by reduced factor VIII binding ability [5] . Gastrointestinal bleeding is a severe complication of VWD often stemming from angiodysplasia of the small bowel. In up to 10% of cases, VWD is associated with angiodysplasia. Although the incidence of angiodysplasia varies across VWD subtypes, it is most frequently reported in types 2 and 3 patients [6] . Angiodysplasia is the tortuous growth of dilated, thin-walled mucosal and submucosal veins, venules and capillaries. This pathological manifestation of unregulated angiogenesis creates a fragile vascular network susceptible to rupture. Angiodysplasia can lead to severe epistaxis and hematuria in VWD patients [7, 8] . Disruption of vascular architecture and the resulting intractable bleeding may result in anemia and often requires hospitalization for transfusion of packed red blood cells, with an attendant decrease in quality of life [9] .
interactions between pro and antiangiogenic molecules maintains the development of normal, stable vessel structures. During the early stages of angiogenesis, vascular endothelial growth factor (VEGF)-A binds to VEGF receptor-2 (VEGFR-2) on endothelial cells activating intracellular signalling cascades promoting endothelial cell proliferation and migration [12] . Blood vessel integrity is controlled by angiopoietin (Ang)-1 signalling through Tie-2 receptors [13] . Ang-2 destabilizes the vascular network, working synergistically with VEGF to promote angiogenesis by competitively inhibiting Ang-1 binding to Tie-2 [13] . The extracellular matrix influences blood vessel development using cell surface adhesion molecules, such as integrin receptor avb3: the best-characterized endothelial cell receptor for VWF. Signalling through integrin avb3 can be pro or antiangiogenic depending on the ligand bound [14, 15] .
The study of VWD and angiodysplasia has been advanced by the use of an ex vivo, late blood outgrowth endothelial cell (BOEC) model [10, 16] . BOECs are an accessible source of vascular endothelium that maintain their differentiated phenotype through multiple passages. Like native endothelial cells, BOECs contain WPBs and express endothelial cell surface proteins [17] . BOECs model the pathogenic effects of VWF mutations on VWF synthesis, storage, secretion, and string formation [18] . This study aimed to use BOECs to determine baseline angiogenic capacities in healthy controls and investigate the role of quantitative and qualitative VWF abnormalities on in vitro surrogates for the development of angiodysplasia.
Methods

Controls and patients
Eligible study participants were recruited during clinic visits. Inclusion criteria included a history of excessive bleeding as documented by a bleeding score at least 4 using the condensed Molecular and Clinical Markers for the Diagnosis and Management-1 VWD bleeding assessment tool [19] , and for type 1 VWD, normal VWF multimers, and VWF:Ag and/or VWF:RCo between 0.05 and 0.50 IU/ml. Type 2 patients had VWF:RCo or factor VIII:C of less than 0.50 IU/ml. Type 3 study participants had plasma VWF:Ag and/or VWF:RCo less than 0.05 IU/ ml, and factor VIII:C of less than 0.10 IU/ml. Healthy, non-VWD controls were included with VWF:Ag, VWF:RCo, and factor VIII:C more than 0.50 IU/ml, a bleeding score of less than 4 and no VWF mutations. Controls with a previous diagnosis of an inherited bleeding disorder, or those with an acquired cause of bleeding (low platelets, renal or liver disease) were excluded.
Upon enrolment, bleeding score were calculated and VWF and factor VIII levels were measured. Data presented in this paper represents factor levels measured at the time of BOEC isolation. This study was approved by the Research Ethics Board of Queen's University, Kingston, Canada and all participants gave written informed consent.
Blood outgrowth endothelial cell isolations BOEC isolations were performed according to published methods with modifications [17] . Mononuclear cells were isolated using BD Vacutainer Cell Preparation Tubes (BD Biosciences, Franklin Lakes, NJ, USA), washed and resuspended in EBM-2 (Lonza, Walkersville, MD, USA) supplemented with 10% fetal bovine serum, 1% antibiotics (Invitrogen, Carlsbad, CA, USA), and the EGM-2 bullet kit [complete endothelial cell growth medium (cEGM)-2]. 4 Â 10 7 cells/well were seeded on collagen-coated six-well tissue culture plates. After 9-21 days, BOECs appeared with characteristic cobblestone morphology. BOECs were used between passages 3 and 9 after flow cytometry characterization for CD31 þ , CD14 À , CD45 À , CD144 þ , and/or CD146 þ . All antibodies were purchased from eBiosciences (San Diego, California, USA).
Von Willebrand factor and angiopoietin-2 expression and secretion BOECs were seeded, 1 Â 10 6 cells/well, in EGM-2 on a six-well collagen-coated plate. After 24 h, media was changed to serum free Opti-MEM (Life Technologies, Carlsbad, CA, USA) supplemented with 100 mg/l calcium chloride. After 24 h, media and lysates were collected and levels of intracellular and secreted VWF and Ang-2 were quantified by ELISA, using polyclonal antibodies (VWF A0082 and P226, DAKO, Mississauga, Ontario, Canada) and the Human Angiopoitein-2 Duoset ELISA kit (R&D Systems Minneapolis, Minnesota, USA), respectively.
Quantitative real-time PCR RNA was isolated from confluent BOECs using the QIAamp RNA Blood Mini Kit (QIAGEN, Hilden, Germany). Quantitative real-time PCR (qRT-PCR) was carried out using the following primers to
, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (5 0 -CAAGGTCATCCATGACAACTTTG-3 0 , 5 0 -GGG-CCATCCACAGTCTTCTG-3 0 ). One healthy control was used to establish normal mean and range; each VWD sample from single isolations was tested in double. PCR reaction was run using the SuperScript III Platinum SYBR Green One-Step qRT-PCR Kit (Invitrogen) on a ViiA 7 Real-Time PCR System with a 96-well block.
Proliferation assay
BOECs were seeded, 4000 cells/well, in cEGM-2 onto three separate collagen-coated black-bottomed 96-well plates. At each of 48, 96, and 144 h, media was removed from one plate and the plate was frozen at À808C to initiate lysis of the cells. All three plates were thawed within 4 weeks of freezing and the cell number at 48, 96, and 144 h was quantified separately with the fluorescence-based CyQuant Cell Proliferation Assay Kit ViiA 7 Real-Time PCR Sytem (Life Technologies, Carlsbad, CA, USA).
Scratch-wound healing assay
BOECs were seeded, 3.5 Â 10 4 cells/well, onto collagencoated ImageLock 96-well plates (Essen Biosciences Inc., Ann Arbor, MI, USA) in cEGM-2. After 12 h, confluent monolayers were scratched using the WoundMaker tool (Essen Biosciences, Inc.). The wells were washed and cEBM-2 was added. Images were captured at 30 min intervals using the Incucyte ZOOM 4X objective (Essen Biosciences, Inc.). The migration paths of 10 random cells at the upper border of the wound were recorded using the Manual Tracking plugin for Fiji. Data from the first 15 h was used to quantify Euclidean distance, migration velocity, and directionality using the stand-alone Chemotaxis and Migration tool (Ibidi, Martinsried, Germany).
Matrigel tubule formation assay
In. total, 48-well plates were coated with Matrigel (Corning Inc., Corning, NY, USA) and polymerized for at least 30 min before use. BOECs were seeded (5 Â 10 4 cells/ well) in duplicate onto the Matrigel. After 8 and 20 h at 378C, cells were imaged at 4X magnification on a Nikon TE-2000U (Melville, NY, USA) inverted microscope.
Tubules were characterized using the online software program WimTube (Wimasis Image Analysis, Ibidi) [20] .
Statistical analysis
Graphing and statistical analyses were performed with Prism 6 for Mac (GraphPad Software Inc, La Jolla, CA, USA) (version 6.0c). The data was collected from at least three distinct experiments and presented as means AE SD. Data sets were analyzed using the Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test and nonparametric Mann-Whitney tests. Sample size for each experiment is stated in the figure legends.
Results
Healthy controls and von Willebrand disease patients BOECs were isolated from 10 healthy controls (C-1 to C-10) and 13 VWD patients: four type 1 (T1-1 to T1-4), one each of type 2A, 2B, 2M, type 2N, and five type 3 (T3-1 to T3-5). Laboratory characteristics and VWF mutations pertaining to each individual are displayed in Table 1 .
Blood outgrowth endothelial cell phenotypic characterization BOECs isolated from the 10 healthy controls and 13 VWD patients appeared 9-21 days after isolation with the cobblestone morphology typical of endothelial cells (Fig. 1a) . Flow cytometry of BOECs indicated that all BOECs were highly positive for endothelial cell markers CD31, CD144, and/or CD146 with no indication of leukocyte antigens CD45 and CD14 (Supplemental Table. S1, http://links.lww.com/BCF/A32). BOECs also express the endothelial marker, VE-cadherin, as shown in Fig. 1 .
Von Willebrand factor expression and storage in blood outgrowth endothelial cells BOECs were assessed for intracellular and constitutively released VWF protein from cell lysates and culture supernatants. Although intracellular and basally released VWF levels varied within the control BOEC group (range, 353-841 mU/ml and 11-51 mU/ml, respectively; Supplemental , http:// links.lww.com/BCF/A32). On average, the 10 control BOECs released 31 AE 11 mU/ml VWF, about 5% of their total VWF content of 558 AE 154 mU/ml. Confocal immunofluorescence (IF) microscopy of control BOECs showed VWF staining that was localized to WPBs with minimal diffuse staining (Fig. 1c) .
As with the control BOECs, there was a significant positive correlation between type 1 patient plasma VWF:Ag and released VWF protein levels from BOECs mRNA indicated that three of the four type 1 BOECs (T1-1, T1-3, and T1-4) had reduced VWF expression when compared to a healthy control (Fig. 2b ). In the fourth type 1 VWD patient, T1-2, VWF mRNA levels were three times as high as the control and did not correspond with elevated VWF in the patient's plasma or BOECs. Although the four type 1 patient BOECs (T1-1 to T1-4) had variable constitutive VWF release ( Fig. 2c ), these differences are reflective of varying patient plasma VWF:Ag levels ( Table 1) . BOECs from patients T1-1 and T1-2, who had low plasma VWF:Ag (0.27 IU/ml and 0.14 IU/ml, respectively), displayed significantly reduced VWF release when compared to controls (T1-1 ¼ 14 AE 2 mU/ml, P < 0.001 and T1-2 ¼ 5 AE 4 mU/ml, P < 0.0001). T1-3 and T1-4 who had normal and mildly reduced plasma VWF levels (0.53 IU/ml and 0.44 IU/ml, respectively) had VWF release that was comparable to the healthy controls (35 AE 14 mU/ml and 44 AE 4 mU/ml, respectively). Significant intracellular VWF retention was observed in T1-1 (902 AE 281 mU/ml, P < 0.001) and T1-4 (871 AE 105 mU/ml, P < 0.0001) BOECs, whereas T1-2 had significantly decreased intracellular protein (19 AE 12 mU/ml, P < 0.0001) and T1-3 had VWF levels similar to controls (603 AE 148 mU/mL). Confocal IF microscopy shows the heterogeneity of type 1 VWD BOECs with respect to WPBs formation in line with previously published reports [18, 21] (Fig. 2a) . T1-1 and T1-2 BOECs displayed diffuse VWF staining in addition to some VWF localized to WPBs consistent with heterozygosity for VWF propeptide mutations [21] , whereas T1-3 and T1-4, had intracellular VWF staining that closely resembled the controls. Storage, gene expression, and constitutive release of Ang-2 and VWF in BOECs from four type 1 VWD patients. (a) Confocal Immunofluorescence co-staining of VWF in green (column 1) and Ang-2 in red (column 2) with blue DAPI nuclear stain in the BOECs. Areas of co-localization of VWF and Ang-2 appear yellow in merge images (column 3). (b) qRT-PCR with primers specific for VWF and Ang-2 were performed on RNA isolated from BOECs from one healthy control and VWD patients. VWF and Ang-2 expression was normalized to GAPDH, and then all VWD samples were normalized to one healthy control. Intracellular and constitutively released VWF (c) and Ang-2 (d) of 10 control BOECs (data averaged) and VWD patients. Protein levels were normalized to cell counts. Each value represents the mean AE standard deviation of triplicate or quintuplicate measurements as determined by ELISA. Black bars, controls; dark grey bars, type 1 VWD BOECs. Ã P < 0.05, ÃÃ P < 0.01, ÃÃÃ P < 0.001, ÃÃÃÃ P < 0.0001 vs Controls as indicated by the Mann-Whitney U test.
Type 2 VWD is a diverse subtype encompassing a wide range of qualitative VWF defects. BOECs from all four type 2 VWD subtypes displayed increased VWF expression when compared to a healthy control (Fig. 3b) . Although, intracellular VWF levels of type 2A BOECs (500 AE 104 mU/ml; Fig. 3c ) were comparable with those in control BOECs, type 2A BOECs manifested significantly impaired basal VWF release (11 AE 1 mU/ml, P < 0.0001) compared with control BOECs, consistent with very low plasma VWF (VWF:Ag ¼ 0.07 IU/ml). In type 2A BOECs, VWF staining localized to rounded WPBs and was diffuse with a perinuclear dispersion (Fig. 3a) . While, the type 2B VWD patient has low plasma VWF levels (0.40 IU/ml), this was not reflected in the BOEC model, because of the absence of platelets and a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). In vivo, the presence of platelets and ADAMTS13 would result in increased clearance from the blood because of the formation of platelet-VWF complexes. Hence, there were no observable differences with respect to VWF release of the type 2B BOECs (36 AE 15 mU/ml) relative to the controls (Fig. 3c) . VWF storage appeared normal in the type 2B BOECs, with the protein being stored in WPBs with little diffuse staining (Fig. 3a) . In the type 2M BOECs, despite low plasma VWF:Ag of 0.11 IU/ml, constitutive VWF release (33 AE 3 mU/ml) was equivalent to the controls (Fig. 3c) . Nonetheless, significant VWF retention was also observed in these cells (1321 AE 138 mU/ml, P < 0.0001) and VWF staining indicated the presence of dispersed cytoplasmic distribution (Fig. 3a) . Type 2N BOECs had normal VWF release (33 AE 7 mU/ml) associated with significantly increased VWF retention (829 AE 138 mU/ml, P < 0.001) and VWF Storage, gene expression, and constitutive release of Ang-2 and VWF in BOECs from four type 2 VWD patients (one type 2A, one type 2B, one type 2M, and one type 2N). (a) Confocal Immunofluorescence co-staining of VWF in green (column 1) and Ang-2 in red (column 2) with blue DAPI nuclear stain in the BOECs. Areas of co-localization of VWF and Ang-2 appear yellow in merge images (column 3). (b) qRT-PCR with primers specific for VWF and Ang-2 were performed on RNA isolated from BOECs from one healthy control and VWD patients. VWF and Ang-2 expression was normalized to GAPDH, and then all VWD samples were normalized to one healthy control. Intracellular and constitutively released VWF (c) and Ang-2 (d) of 10 control BOECs (data averaged) and VWD patients. Protein levels were normalized to cell counts. Each value represents the mean AE standard deviation of triplicate or quintuplicate measurements as determined by ELISA. Black bars, controls; light grey bars, type 2 VWD BOECs.
Ã P < 0.05, ÃÃ P < 0.01, ÃÃÃ P < 0.001, ÃÃÃÃ P < 0.0001 vs Controls as indicated by the Mann-Whitney U test.
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storage visualized through confocal IF microscopy appeared normal in type 2N BOECs with little diffuse staining (Fig. 3a) .
VWF expression was reduced in four of five type 3 VWD BOEC (Fig. 4b) . Correspondingly, in the type 3 VWD BOEC with reduced VWF expression, VWF release was negligible (T3-1 ¼ 1.17 AE 0.21 mU/ml, T3-2 ¼ 0.86 AE 0.49 mU/ml, and T3-4 ¼ 1.27 AE 0.32 mU/ml) as was intracellular retention (T3-1 ¼ 2.30 AE 2.29 mU/ml, T3-2 ¼ 7.70 AE 1.59 mU/ml, and T3-4 ¼ 29.36 AE 6.04 mU/ml; P < 0.0001 for all; Fig. 4c ). Despite these negligible VWF protein levels, confocal images of T3-1, T3-3, and T3-4 BOECs show the presence of VWF (Fig. 4a) Fig. 4c ), BOECs from this individual have significantly increased levels of intracellular VWF (1208 AE 190 mU/ml; P < 0.0001; Fig. 4c ). The confocal IF of cells from this patient show a lack of WPB formation and diffuse perinuclear staining (Fig. 4a) .
Enhanced angiopoietin-2 secretion in type 1 and 3 blood outgrowth endothelial cells BOECs were also evaluated for Ang-2 expression, storage, and release to determine if the specific mutations imparting aberrant storage of VWF also affect Ang-2.
Angiogenesis Storage, gene expression, and constitutive release of Ang-2 and VWF in BOECs from five type 3 VWD patients. (a) Confocal Immunofluorescence co-staining of VWF in green (column 1) and Ang-2 in red (column 2) with blue DAPI nuclear stain in the BOECs. Areas of co-localization of VWF and Ang-2 appear yellow in merge images (column 3). (b) qRT-PCR with primers specific for VWF and Ang-2 were performed on RNA isolated from BOECs from one healthy control and VWD patients. VWF and Ang-2 expression was normalized to GAPDH, and then all VWD samples were normalized to one healthy control. Intracellular and constitutively released VWF (c) and (Fig. 1c) .
qRT-PCR results demonstrated increased Ang-2 expression (Fig. 2b ) compared with control BOECs in three of the four type 1 VWD BOECs (T1-1, T1-2, and T1-4). Correspondingly, T1-1, T1-2, and T1-4 also had significantly higher levels of basally secreted Ang-2 (23 AE 6 ng/ ml, P < 0.0001; 13 AE 2ng/ml, P < 0.01; and 23 AE 6 ng/ml, P < 0.0001, respectively; Fig. 2d ). Conversely, BOECs from T1-3 had comparatively less basally secreted Ang-2 (4 AE 2 ng/ml, P < 0.05; Fig. 2d ) associated with reduced gene expression. Confocal IF identified more discrete Ang-2 staining in T1-1, T1-2, and T1-4 than in T1-3 BOECs which had diffuse Ang-2 staining (Fig. 2a) . Furthermore, the confocal images show higher amounts of Ang-2 staining in T1-1 and T1-4 which support that despite very high Ang-2 release, T1-1 and T1-4 also had significantly higher retention of the protein when compared with the controls (176 AE 47 ng/ml and 127 AE 26 ng/ml, respectively; P < 0.0001 for both; Fig. 2d ).
Ang-2 expression was significantly increased in all type 2 BOECs with the greatest expression in type 2A and 2B BOECs (Fig. 3b) . Correspondingly, 2A and 2B BOECs exhibited approximately a two-fold increase in Ang-2 secretion compared with controls (12 AE 3 ng/ml, P < 0.01 for both; Fig. 3d ). This enhanced Ang-2 secretion was associated with normal levels of intracellular Ang-2 in the 2A BOECs (27 AE 7 ng/ml) and significantly higher levels in the 2B BOECs (118 AE 15 ng/ml, P < 0.0001). In line with this, confocal IF data indicated that the Ang-2 staining in the 2A BOECs was discrete and more closely resembled the control BOECs, whereas in the 2B BOECs, Ang-2 was diffuse throughout the cell (Fig. 3a) . In the type 2M BOECs, normal basal Ang-2 release (9 AE 2 ng/ml) was associated with significantly increased retention of the protein (72 AE 21 ng/ml, P < 0.0001) and IF staining was similar to the 2B BOEC with diffuse Ang-2 staining alongside some limited WPBs. Although, the type 2N BOECs also had normal Ang-2 secretion (6 AE 1 ng/ml), this was associated with increased retention of the protein (56 AE 10ng/ml, P < 0.05) despite confocal images indicating that most of the Ang-2 colocalized with VWF.
Ang-2 expression was elevated in all the type 3 BOECs (Fig. 4b) . However, basal Ang-2 secretion was only increased in T3-1 and T3-2 (10 AE 3 ng/ml and 16 AE 6 ng/ml; Fig. 4d ) which show very little intracellular Ang-2 staining (Fig. 4a ). Protein data (Fig. 4d) shows that secretion and intracellular stores of Ang-2 were reduced in the T3-3 (2.8 AE 0.4 ng/ml and 0.4 AE 0.2 ng/ml, respectively) and T3-4 BOECs (3 AE 2 ng/ml and 8 AE 7 ng/ml, respectively) despite confocal images that show an abundance of intracellular Ang-2 (Fig. 4a) .
Improved integrin function in type 1 and 2N von Willebrand disease blood outgrowth endothelial cells
To examine the relationship between VWF mutation and integrin function, BOEC binding to collagen, gelatin, or VWF-coated surfaces was measured (Fig. 5) . Adhesion of control BOECs was greater to the b1 integrin ligand collage type I (14 AE 6% of cells), then to gelatin (11 AE 5% of cells) or VWF (7 AE 6% of cells; Fig. 5a -c).
Endothelial cell binding to collagen is mediated in part by integrin aVb1 and as expected similar number of control versus VWD BOECs were retained to the collagen-coated surface. One type 1 BOEC, T1-1, and the 2N BOECs had significantly increased adherence to the aVb3-dependant substrates VWF (18 AE 8 and 15 AE 3% of cells, respectively, P < 0.05 for both) and gelatin Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
(18 AE 7 and 19 AE 4% of cells, respectively, P < 0.05 for both). A functional defect of aVb1 integrin was observed in one type 3 VWD BOECs, T3-2, as reduced binding to gelatin was observed (5 AE 3% of cells, P < 0.05).
Blood outgrowth endothelial cell proliferation
To assess BOEC proliferation, cell numbers were assessed at 48, 96, and 144 h (Fig. 6) . Rates of proliferation were variable between normal controls but on average, BOECs showed a five-fold increase in cell numbers over 48 h and a further doubling by 144 h (Supplemental Fig. S4 , http://links.lww.com/BCF/A32). Type 2A (52208 AE 2661 cells; P < 0.001) and 2B (55143 AE 2132 cells, P < 0.001) were significantly more proliferative after 144 h but one type 1 BOEC (T1-3 ¼ 11376 AE 3167 cells; P < 0.01) and two of the type 3 BOECs (T3-3 ¼ 17860 AE 4056 cells, P < 0.01 and T3-4 ¼ 4974 AE 1822 cells, P < 0.001) were significantly less proliferative compared to control BOECs.
Type 1 and type 3 von Willebrand disease blood outgrowth endothelial cells display increased directionality and reduced velocity BOEC migration was assessed using a scratch-wound healing assay (Fig. 7) . The Euclidean distance (Fig. 7a) is a measure of the direct linear distance between the start and end point of a cell's trajectory. This measure of cellular migration did not vary significantly between the 10 control BOECs and averaged 219 AE 50 mm (Supplemental Fig. S4d Figure 7d displays cell trajectory plots for 10 randomly chosen individual cells from the upper border of the wound for control and patient BOECs. These plots demonstrate that the average BOEC migration in all BOECs was toward the wound (in the negative y direction). Ultimately, the migration data reveal that the type 1 and 3 BOECs had reduced mean cell front migration velocity and increased directionality than the control and type 2 VWD BOECs.
Impaired tubule formation in type 1, 2B, and type 3 blood outgrowth endothelial cells Vessel formation was evaluated through three-dimensional BOEC cultures in Matrigel by characterizing total tubule length eight hours after seeding (Table 2 and Supplemental Fig. S1 , http://links.lww.com/BCF/A32). There was great variability in vessel formation in the 10 controls ranging from 3 to 100 mm (mean ¼ 59 AE 23 mm). When the individual control BOECs were compared, tubule formation was the greatest in two young (ages 26-31) female donors, and four of the six female donors were above the average tubule length (Supplemental Fig. S4b , http://links.lww.com/BCF/A32). Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Angiogenesis in von
With respect to the BOECs from VWD patients, T1-1 (25 AE 18 mm, P < 0.05), 2B (22 AE 8 mm, P < 0.05), T3-1 (13 AE 6 mm, P < 0.01), and T3-2 (27 AE 17 mm, P < 0.05) BOECs formed significantly shorter tubules than the control BOECs 8 h after seeding. These BOECs also had significantly less branching points, loops, and tubes (Table 2) . Interestingly, despite variations in total tube lengths, mean tube length was mostly conserved across all BOECs. Unlike the control BOECs, we did not observe a difference in tube formation between women and men as BOEC from half of the female patients had above average tubule length and the other half had below average tubule formation.
Discussion
VWF has been characterized as a negative regulator of angiogenesis and is suggested to act through two pathways involving Ang-2, integrin avb3, and VEGFR-2 signalling [10] . The intracellular pathway involves sequestering Ang-2 to WPBs, preventing its interactions with Tie-2 receptors and thereby reducing cellular proliferation. Second, extracellular interactions between VWF and its integrin avb3 inhibit proliferative signalling through VEGFR-2 [10] . The current study examining the angiogenesis of BOECs derived from control and VWD patients is the largest to date. Overall, our results indicate that there is great variability in the angiogenic properties of both control and VWD BOECs. Abnormal cell proliferation, migration, and increased Ang-2 secretion are common features of endothelial cells derived from the BOECs of VWF patients. Type 1 and 3 BOECs had reduced mean cell front migration velocity and increased directionality as compared with control BOECs. However, even within a single VWD type, BOECs from different patients presented with diverse angiogenic characteristics. These findings are consistent with recent studies of BOECs from VWD patients which also showed great interindividual variability of angiogenic capacity [16] .
Ang-2 promotes VEGF-dependent stimulation of endothelial cell sprouting and migration [22] and induces degradation of integrin b3 [23] . In siVWF-treated human umbilical vein endothelial cells (HUVECs), Ang-2 storage, and release were dysfunctional with the loss of VWF [10] . In our study, Ang-2 storage was defective across all VWD BOECs with half of the type 1s, 2A, 2B, and two type 3 VWD BOECs displaying increased secretion. Interestingly, our highest Ang-2 levels were observed in two type 1 BOECs and not in type 3 BOECs, where VWF levels were negligible, suggesting that defective Ang-2 storage because of mutations in the VWF gene are not primarily responsible for the regulation of endothelial Ang-2 release. In fact, these BOECs also had elevated expression of the Ang-2 gene which would have contributed to the increased secretion; the reason for this is not clear.
Our results indicate that type 1 and 3 VWD BOECs with significantly increased Ang-2 basal release have increased cell migration directionality and decreased velocity. In contrast, type 2 BOECs with both increased and normal Ang-2 secretion migrated with increased velocity and impaired directionality toward to wound, as observed in siVWF-treated HUVECs [10] . Groeneveld et al. found that while VWD BOECs did not differ from control BOECs with respect to migration velocities, they all displayed a loss of directionality when compared with control BOECs [16] . Variations in multiple angiogenic factors and VWF mutations in these BOECs could differentially influence the migration characteristics of these cells. VEGF and fibroblast growth factor have been known to coordinate and promote the chemotaxis of endothelial cells [24] , and thus it may be of interest to monitor the levels of these agents in the BOECs to determine whether their expression is reduced and could be contributing to the reduced migration velocity. Physiologically, the shear stress of fluid flowing through blood vessels also functions to mediate endothelial cell migration [24] . The lack of this modulation in the migration assay in vitro could have also impacted the migration properties of these BOECs.
Starke et al. showed that BOECs from VWD patients have increased VEGF-dependent proliferation and this was the case for the type 2A and 2B BOECs in our study [10] . In fact, BOECs with significantly reduced Ang-2 release compared with controls displayed significantly reduced cell numbers 144 h after seeding.
Given that internalization of the b3 subunit of integrin avb3 is augmented in VWF deficiency [10] and b3 subunit loss corresponds with increased angiogenesis in mice [25] , decreased adhesion of BOECs to integrin avb3-dependent substrates gelatin [26] and VWF was expected. Although adhesion to the different integrin mediators was comparable across BOECs, one type 3 VWD BOEC displayed reduced binding to gelatin suggesting impaired integrin function. We also observed that one type 1 and the type 2N BOECs were more adhesive to gelatin and VWF indicating improved integrin function. This unexpected result may be further explored through measurement of gene expression and surface levels of integrin b3 to assess interindividual variation in integrin abundance on adhesion. Additionally, adhesion to integrin avb3, using vitronectin, could be assessed to better recapitulate the in-vitro integrin avb3-mediated adhesion of endothelial cells.
Finally, the ability of BOECs to form tubules in three dimensional Matrigel which combines multiple aspects of endothelial cell angiogenesis [20] was observed. In control BOECs, there was great variability in terms of total tubule length which did not correlate significantly with VWF level, Ang-2 release, or donor age. Yet, BOECs isolated from women formed more tubules than those from men. This finding compliments previous studies that report that BOECs from women exhibit greater [10, 16] . Our results are consistent with the latter findings as BOECs isolated from one type 1, the 2B, and two type 3 patients had significantly reduced total tubule formation. The variability in tubule formation may be attributed to a number of different factors including cell passage, as higher passage BOECs have declining abilities to form tubules [16] .
BOECs are a relatively new model for studying endothelial cell-dependent processes ex vivo and the range of what constitutes 'normal' VWF expression and angiogenesis for these cells is not yet well established. Absent in vitro is ADAMTS13, which results in higher degrees of multimerization in BOEC VWF than plasma. Additionally, variances in BOEC VWF levels may be attributed to interindividual differences in the VWF gene and other modifiers. It is difficult to isolate the effects of VWF on angiogenesis in BOECs because their interindividual variability affects all expression profiles including many other angiogenic regulators. Even between siblings C-9 and C-10, Ang-2 expression/release, adhesion and permeability diverged greatly, despite similarities in VWF expression and tubule formation. Additionally, variability of BOEC Ang-2 release may be attributed to factors other than VWF. For instance, Ang-2 expression is elevated by many diseases with known endothelial dysfunction, including hypertension and atherosclerosis [28] . The isolation and culturing process of BOECs may contribute to the varied angiogenic responses between donors. The quality of the BOEC cultures, cell size, time to confluence, cell density at confluence, and/or variation in BOEC passages may have influenced cellular performance on the angiogenesis and VWF-processing assays [16] .
Our study included relatively small numbers of BOECs. Indeed, with a single BOEC line for each type 2 VWD subtype, we are unable to generalize our findings to all type 2 VWD. This, plus the variability observed limits generalization of the results. Although a larger sample size might help overcome this concern, access to larger numbers of patients, and the resource-intensive nature of endothelial cell experiments are barriers. Additionally, given that the stages of angiogenesis do not function in isolation from each other, assays measuring only one aspect of angiogenesis are artificial. Angiogenesis is a complex process relying on delicate interplay between hundreds of molecules [29] . An imbalance of any of these molecules in the pro or antiangiogenic direction can cause abnormal angiodysplastic vessel growth. It is unlikely that the pathogenesis of angiodysplasia in VWD can be characterized by a change in BOEC behaviour in one assay. With these limits in mind, BOECs do provide access to patient vascular endothelium and enable the study of cellular interactions of VWF with other angiogenic mediators. The results of this study further validate the use of BOECs as investigative models of patient and individual-specific differences in VWF expression patterns and angiogenesis. The future use of physiologically representative assays, such as the fibrin bead model of sprouting angiogenesis, could help to further define the aberrant qualities of angiogenesis occurring in VWD patients [30] and complement studies in BOECs. Perhaps the most valuable use of the BOEC model is in their therapeutic applications for VWD. BOECs could be used for the optimization of patient-specific treatment regimens in VWD patients with the goal of lessening the considerable burden of gastrointestinal bleeding in VWD.
